| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6440990 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2013
(10 years ago) | |
|
US6440990 (Pediatric) | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2014
(10 years ago) | |
| US6004973 | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul, 2016
(7 years ago) | |
|
US6004973 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan, 2017
(7 years ago) | |
| US6455518 | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
Jul, 2017
(6 years ago) | |
| US6239124 | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
Aug, 2017
(6 years ago) | |
|
US6455518 (Pediatric) | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
Jan, 2018
(6 years ago) | |
|
US6239124 (Pediatric) | NOVARTIS | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
Feb, 2018
(6 years ago) | |
| US5665772 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) | |
|
US5665772 (Pediatric) | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2020
(4 years ago) | |
Zortress is owned by Novartis.
Zortress contains Everolimus.
Zortress has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Zortress are:
- US6440990
- US6440990*PED
- US6004973
- US6004973*PED
- US6455518
- US6239124
- US6455518*PED
- US6239124*PED
- US5665772
- US5665772*PED
Zortress was authorised for market use on 20 April, 2010.
Zortress is available in tablet;oral dosage forms.
Zortress can be used as prophylaxis of allograft rejection in adult patients receiving a liver transplant, prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a renal transplant.
Drug patent challenges can be filed against Zortress from 30 September, 2013.
The generics of Zortress are possible to be released after 09 March, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 20, 2013 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-668) | Feb 15, 2016 |
| Pediatric Exclusivity(PED) | Oct 20, 2013 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 30 September, 2013
Market Authorisation Date: 20 April, 2010
Treatment: Prophylaxis of allograft rejection in adult patients receiving a liver transplant; Prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a renal transplant
Dosage: TABLET;ORAL
ZORTRESS family patents
